Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

1
Urinary Tract Infections (UTI) Therapeutics -
Pipeline Assessment and Market Forecasts to 2018

• Aarkstore Enterprise specialize in providing
  online market business information on market
  research reports, books, magazines, conference
  booking at competitive prices, and strive to
  provide excellent and innovative service to our
  customers.

2
Urinary Tract Infections (UTI) Therapeutics -
Pipeline Assessment and Market Forecasts to 2018

• Date 29 February 2012
• Pages 72
• SummaryUrinary Tract Infections (UTI)
  Therapeutics - Pipeline Assessment and Market
  Forecasts to 2018. The report is an essential
  source of information and analysis on the global
  Urinary Tract Infections Therapeutics market. The
  report identifies the key trends shaping and
  driving the global Urinary Tract Infections
  Therapeutics market. The report also provides
  insights on the prevalent competitive landscape
  and the emerging players expected to
  significantly alter the market positioning of the
  current market leaders. Most importantly, the
  report provides valuable insights on the pipeline
  products within the global Urinary Tract
  Infections Therapeutics sector. This report is
  built using data and information sourced from
  proprietary databases, primary and secondary
  research and in-house analysis by Company team of
  industry experts.ScopeThe report provides
  information on the key drivers and challenges of
  the Urinary Tract Infections Therapeutics market.
  Its scope includes - - Annualized seven key
  markets (US, France, Germany, Italy, Spain, UK
  and Japan) Urinary Tract Infections Therapeutics
  market revenues data from 2005 to 2010, forecast
  for eight years to 2018. - Pipeline analysis
  data providing a split across the different
  phases, mechanisms of action being developed and
  emerging trends by seven key markets. Pipeline
  candidates fall under major therapeutic
  classes.- Analysis of the current and future
  competition in the seven key countries Urinary
  Tract Infections Therapeutics market. -
  Insightful review of the key industry drivers,
  restraints and challenges. Each trend is
  independently researched to provide a qualitative
  analysis of its implications. - Key topics
  covered include strategic competitor assessment,
  market characterization, unmet needs and the
  implications for the Urinary Tract Infections
  Therapeutics market.- Analysis of key recent
  licensing and partnership agreements in Urinary
  Tract Infections Therapeutics market 

3
Urinary Tract Infections (UTI) Therapeutics -
Pipeline Assessment and Market Forecasts to 2018

• Reasons to buyThe report will enhance your
  decision making capability. It will allow you to
  - - Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies and by
  identifying the companies with the most robust
  pipeline. - Develop business strategies by
  understanding the trends shaping and driving the
  global Urinary Tract Infections Therapeutics
  market. - Drive revenues by understanding the
  key trends, innovative products and technologies,
  market segments and companies likely to impact
  the global Urinary Tract Infections Therapeutics
  market in future. - Formulate effective sales
  and marketing strategies by understanding the
  competitive landscape and by analyzing the
  performance of various competitors. - Identify
  emerging players with potentially strong product
  portfolios and create effective
  counter-strategies to gain a competitive
  advantage. - Organize your sales and marketing
  efforts by identifying the market categories and
  segments that present maximum opportunities for
  consolidations, investments and strategic
  partnerships. - What the next big thing in the
  global Urinary Tract Infections Therapeutics
  market landscape? Identify, understand and
  capitalize.

4
1.1 List of Tables 51.2 List of Figures 62 UTI
Therapeutics - Introduction 72.1 Overview 72.2
Classification of UTI 72.2.1 Site of Infection
82.2.2 Based On Symptoms 82.2.3 Based on
Recurrence 82.2.4 Based on Complicating Factors
82.2.5 Based on Origin of Infection 82.3
Epidemiology 92.4 Etiology 102.5 Risk Factors
102.6 Signs and Symptoms 112.7 Pathophysiology
of UTI 112.8 Diagnosis and Treatment of UTI
122.9 GlobalData Pipeline Report Guidance 163
UTI Therapeutics - Market Characterization 173.1
UTI Therapeutics Market Size (2005-2010) - Global
173.2 UTI Therapeutics Market Forecast
(2010-2018) - Global 193.3 UTI Therapeutics
Market Size (2005-2010) - The US 213.4 UTI
Therapeutics Market Forecast (2010-2018) - The US
223.5 UTI Therapeutics Market Size (2005-2010) -
France 233.6 UTI Therapeutics Market Forecast
(2010-2018) - France 243.7 UTI Therapeutics
Market Size (2005-2010) - Germany 253.8 UTI
Therapeutics Market Forecast (2010-2018) -
Germany 263.9 UTI Therapeutics Market Size
(2005-2010) - Italy 273.10 UTI Therapeutics
Market Forecast (2010-2018) - Italy 283.11 UTI
Therapeutics Market Size (2005-2010) - Spain
293.12 UTI Therapeutics Market Forecast
(2010-2018) - Spain 303.13 UTI Therapeutics
Market Size (2005-2010) - The UK 313.14 UTI
Therapeutics Market Forecast (2010-2018) - The UK
323.15 UTI Therapeutics Market Size (2005-2010)
- Japan 333.16 UTI Therapeutics Market Forecast
(2010-2018) - Japan 343.17 Drivers and Barriers
for the UTI Therapeutics Market 35
5

3.17.1 Drivers for the UTI Therapeutics Market
353.17.2 Barriers for the UTI Therapeutics
Market 353.18 Key Events Impacting the Future
Market 363.19 Opportunity and Unmet Need 363.20
Key Takeaway 374 UTI Therapeutics Market -
Competitive Assessment 384.1 Overview 384.1.1
Strategic Competitor Assessment 384.2 Profiles
of Commonly Used Products in the UTI Therapeutics
Market 394.2.1 Ciprofloxacin 394.2.2 Doribax
(doripenem) 404.2.3 Invanz (ertapenem sodium)
414.2.4 Levaquin (levofloxacin) 424.2.5
Fosfomycin tromethamine 424.2.6
Macrobid/Macrodantin (nitrofurantoin) 434.2.7
Bactrim/Septra (trimethoprim/sulfamethoxazole)
444.3 Key Takeaway 445 UTI Therapeutics Market
- Pipeline Assessment 455.1 Overview 455.2
Strategic Pipeline Assessment 455.2.1 UTI
Therapeutics - Phase III Pipeline 465.2.2 UTI
Therapeutics - Phase II Pipeline 465.2.3 UTI
Therapeutics Phase I Pipeline 465.3 UTI
Pipeline by Mechanism of Action 475.4 UTI
Technology Trends Analytical Framework 485.5 UTI
Therapeutics - Late-stage Drugs under Clinical
Development 495.6 Molecule Profile for
Late-stage Drugs under Clinical Development
505.6.1 CXA-201 (CXA-101/tazobactam) 505.6.2
CAZ-AVI (Avibactam/ceftazidime) 505.7 Key
Takeaway 516 UTI Therapeutics - Clinical Trials
Mapping 526.1 Clinical Trials by Country (US,
EU5 and Japan) 526.2 Clinical Trials by Phase
536.3 Clinical Trials by Trial Status 546.4
Overall Sponsors 55
6

6.5 Prominent Sponsors 566.6 Top Companies
Participating in UTI Therapeutics Clinical Trials
577 UTI Therapeutics - Strategic Assessment
587.1 UTI Therapeutics - Implications for Future
Market Competition 588 UTI Therapeutics - Future
Players 598.1 Introduction 598.1.1 AstraZeneca
PLC 598.1.2 Cubist Pharmaceuticals 618.1.3
Forest Laboratories 639 UTI Therapeutics -
Licensing and Partnership Deals 6510 UTI
Therapeutics - Appendix 6710.1 Definitions
6710.2 Acronyms 6710.3 Research Methodology
6810.3.1 Coverage 6810.3.2 Secondary Research
6810.3.3 Forecasting 6910.3.4 Primary Research
7110.3.5 Expert Panel Validation 7110.4 Contact
Us 7110.5 Disclaimer 7110.6 Bibliography 72
7

• For more information, please visit
• http//www.aarkstore.com/reports/Urinary-Tract-Inf
  ections-UTI-Therapeutics-Pipeline-Assessment-and-M
  arket-Forecasts-to-2018-198828.htmlOr email us
  at contact_at_aarkstore.com or call 919272852585
• Related Reports
• Vemurafenib - Comprehensive patent
  search Colesevelam - Comprehensive patent
  search Rifaximin - Comprehensive patent
  search Nevirapine - Comprehensive patent
  search Liraglutide - Comprehensive patent
  search Vilazodone - Comprehensive patent
  search Hexylaminolevulinic Acid - Comprehensive
  patent search Treprostinil - Comprehensive
  patent search Patient Adherence, Communication
  and Engagement (PACE) - Increased Investment and
  Adoption of New Digital Tools Enable Key
  Stakeholder Collaborations and Encourage
  Compliance Express Scripts, Inc.
  Pharmaceuticals and Healthcare Company Profile,
  SWOT and Financial Report

8
Contact Us

• Aarkstore Enterprise
• Tel [phone]
• Mobile No08149852585
• Email contact_at_aarkstore.com
• Website http//www.aarkstore.com
• Blog http//www.emarketreports.com
• http//teju-aarkstoreenterprise.blogspot.in
• Follow us on twitter http//twitter.com/aarkstore
  dotcom
• http//in.linkedin.com/in/aarkstore
• http//www.facebook.com/aarkstoreenterprise